fbpx

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

ASCO Oral: Phase III COSMIC-311 promises a new standard of care for patients with previously treated differentiated thyroid cancer

07/06/2021|Comments Off on ASCO Oral: Phase III COSMIC-311 promises a new standard of care for patients with previously treated differentiated thyroid cancer

ASCO Oral: Landmark study rings in the first immune-based therapy for patients with resected, high-risk early-stage non-small cell lung cancer

07/06/2021|Comments Off on ASCO Oral: Landmark study rings in the first immune-based therapy for patients with resected, high-risk early-stage non-small cell lung cancer

ASCO Plenary: PARPi prevents disease recurrence in BRCA-mutated high-risk, early stage breast cancer

03/06/2021|Comments Off on ASCO Plenary: PARPi prevents disease recurrence in BRCA-mutated high-risk, early stage breast cancer

The COVID-19 pandemic: widening the gender gap in cancer research

25/05/2021|Comments Off on The COVID-19 pandemic: widening the gender gap in cancer research

Cemiplimab steps up as the first immune-based therapy to improve overall survival in patients with recurrent and/or metastatic cervical cancer

12/05/2021|Comments Off on Cemiplimab steps up as the first immune-based therapy to improve overall survival in patients with recurrent and/or metastatic cervical cancer

Launched: VHIO’s Scientific Report 2020. A year of challenges, opportunities and hope

11/05/2021|Comments Off on Launched: VHIO’s Scientific Report 2020. A year of challenges, opportunities and hope

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2020

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS